Antengene's ATG-037 and Selinexor Combo Shows 62% Tumor Growth Inhibition in Multiple Myeloma Study — Antengene Corporation Limited

Event summary

Antengene published preclinical research on ATG-037 (CD73 inhibitor) combined with selinexor for multiple myeloma treatment.
Study showed 62% tumor growth inhibition in mouse models, compared to 31% for ATG-037 alone and 43% for selinexor alone.
Combination therapy enhanced CD8+ T cell activation and tumor cell killing through CD80-CD28 signaling pathway.
Research published in Cancer Gene Therapy journal (DOI: 10.1038/s41417-026-01078-9).
Study conducted in collaboration with Peking University Third Hospital.

The big picture

Antengene's research highlights a strategic push to enhance the efficacy of its commercial asset, selinexor, by combining it with novel therapies like ATG-037. This aligns with broader industry trends toward combination immunotherapies to overcome resistance mechanisms in cancer treatment. The study's publication in a reputable journal underscores the scientific validity of the approach, positioning Antengene as a player in the competitive oncology space.

What we're watching

Clinical Translation: Whether the preclinical results will translate into clinical efficacy in human trials.
Regulatory Pathway: The pace at which Antengene advances ATG-037 through clinical development and potential regulatory approvals.
Commercial Strategy: How Antengene positions this combination therapy in its portfolio alongside its lead commercial asset, selinexor.